Thrivent Financial for Lutherans Has $60.50 Million Stake in Stevanato Group S.p.A. (NYSE:STVN)

Thrivent Financial for Lutherans lowered its stake in Stevanato Group S.p.A. (NYSE:STVN) by 0.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,776,626 shares of the company’s stock after selling 8,286 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Stevanato Group were worth $60,503,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. TimesSquare Capital Management LLC increased its stake in shares of Stevanato Group by 114.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company’s stock valued at $71,657,000 after buying an additional 1,756,100 shares during the period. Jennison Associates LLC acquired a new stake in Stevanato Group in the fourth quarter worth about $20,239,000. Mutual of America Capital Management LLC bought a new stake in Stevanato Group during the 4th quarter worth about $13,848,000. New York State Common Retirement Fund acquired a new position in Stevanato Group during the 4th quarter valued at about $8,879,000. Finally, Conestoga Capital Advisors LLC boosted its stake in shares of Stevanato Group by 5.3% in the 4th quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company’s stock valued at $176,128,000 after purchasing an additional 407,086 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on STVN shares. William Blair reissued an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Wolfe Research started coverage on Stevanato Group in a research note on Friday, December 13th. They issued an “outperform” rating and a $28.00 price target on the stock. UBS Group decreased their price objective on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Morgan Stanley reissued an “equal weight” rating and issued a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Finally, Bank of America boosted their target price on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy” and a consensus price target of €27.75 ($30.16).

Stevanato Group Stock Down 0.1 %

Shares of STVN stock opened at €21.74 ($23.63) on Thursday. Stevanato Group S.p.A. has a 12-month low of €16.56 ($18.00) and a 12-month high of €33.49 ($36.40). The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The firm has a fifty day moving average of €21.08 and a 200-day moving average of €20.59. The company has a market capitalization of $6.58 billion, a price-to-earnings ratio of 46.26, a P/E/G ratio of 7.18 and a beta of 0.60.

Stevanato Group (NYSE:STVN) last released its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of €0.20 ($0.22). The firm had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. As a group, equities research analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.